NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Juno Therapeutics Inc. (“Juno”) (NASDAQ:JUNO) between June 4, 2016 and July 7, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division. If you purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Juno materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015. These omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.
If you suffered a loss in Juno you have until September 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.